The Interagency Registry for Mechanically Assisted Circulatory Support

Intermacs is a North American registry established in 2005 for patients who are receiving mechanical circulatory support device therapy to treat advanced heart failure. Intermacs was established as a joint effort of the National Heart, Lung and Blood Institute (NHLBI), the Food and Drug Administration (FDA), the Centers for Medicare and Medicaid Services, clinicians, scientists and industry representatives in conjunction with Dr. James K. Kirklin and the University of Alabama at Birmingham.

Intermacs collects clinical data relevant to mechanical circulatory support devices (MCSDs) from index hospitalization through follow-up evaluations. Post implant follow-up data is collected at 1 week, 1 month, 3 months, 6 months and every 6 months thereafter. Major outcomes after implant, e.g., death, explant, rehospitalization and adverse events, are entered within 30 days of occurrence and also as part of the defined follow-up scheduled intervals.

Intermacs provides contemporary data to demonstrate outcomes, with additional insight into appropriate risk stratification and patient selection. Death, transplant, and explant are the major discrete endpoints recorded. Complex endpoints include the patient’s level of function and quality of life, critical to the evaluation of current MCSD therapy these indices are becoming increasingly important as patient survival improves, and new devices will be compared for outcomes beyond survival.

As of March 5, 2018

Active Sites
23,787 Patients Enrolled

24 Active Sites
576 Patients Enrolled
Intermacs Login Pedimacs Login Update Contact Info Reporting Request

Intermacs is sensitive to site and participant confidentiality. Please use a secure e-mail to communicate confidential information with Intermacs staff.  If you do not have a secure e-mail available, contact us at and request access to the Intermacs secure e-mail.

This project has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract Number HHSN268201100025C.